Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05848089 · ClinicalTrials.gov registry record · NA
Real-time Intervention for Suicide Risk Reduction
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
NCT05848089: Completed NA study, sponsored by Massachusetts General Hospital.
NCT05848089 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 41 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05848089, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
Study Summary
The aim of this study is to determine whether learning three skills for managing negative emotions and receiving reminders via smartphone to practice these skills reduces how often and how intensely one experiences emotional distress and suicidal thoughts.
Primary Outcome
Overall changes in momentary self-reported intensity of suicidal urges (measured on a 11-point rating scale up to 4x/day via ecological momentary assessment) from pre- to post-EMI use, among those in the experimental condition only
Interventions
- BEHAVIORAL Ecological momentary assessment (EMA)
- BEHAVIORAL Treatment as usual (TAU)
- BEHAVIORAL Brief skills sessions plus EMI skills practice prompts
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-09-25 |
| Est. Completion | 2025-02-19 |
| Phase | NA |
What the finished NCT05848089 record still lists
NCT05848089 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Ecological momentary assessment (EMA) is the first listed.
NCT05848089 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05848089 about?
NCT05848089 is a clinical study titled "Real-time Intervention for Suicide Risk Reduction". The aim of this study is to determine whether learning three skills for managing negative emotions and receiving reminders via smartphone to practice these skills reduces how often and how intensely one experiences emotional distress and suicidal thoughts.
What is the current status of trial NCT05848089?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2023-09-25. Estimated completion is 2025-02-19.
What interventions are being tested in trial NCT05848089?
The interventions under investigation include: Ecological momentary assessment (EMA) (BEHAVIORAL), Treatment as usual (TAU) (BEHAVIORAL), Brief skills sessions plus EMI skills practice prompts (BEHAVIORAL).
Who is sponsoring clinical trial NCT05848089?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05848089's enrollment target sits among peer trials
41 1446th of 2000 higher than 554 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI